retatrutide clinical trial results weight loss Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Weight Loss Results:Trial Data

Rushing the titration leads to worse nausea and higher dropout rates

However, since the medication slows digestion, it can change how other oral medications are absorbed

Options may include switching to a different GLP-1 medication, adjusting the dose, or developing a plan to support weight maintenance through nutrition and behavioral strategies during the gap

Members are encouraged to build strength, protect muscle, stay nourished, and develop habits that support long-term health even after weight loss slows

Fiber supplements may support regular bowel movements, but tolerance varies by fiber type and digestive sensitivity

Kaeberlein's work focuses on the biological processes underlying aging and age-related diseases, offering a fresh perspective on how we can enhance both human and animal health